LGND(Ligand Pharmaceuticals Incorporated) · 财务报表

LGND(Ligand Pharmaceuticals Incorporated) 的财务报表:医疗保健,生物技术。数据来自 SEC 公开申报与市场行情,不构成投资建议。

近年年度财务(SEC XBRL)
科目FY 截至 2021-12-31FY 截至 2022-12-31FY 截至 2023-12-31FY 截至 2024-12-31FY 截至 2025-12-31
营业收入$241.54M$196.25M$131.31M$167.13M$268.09M
毛利润—————
营业利润$103.85M$3.04M$11.94M−$22.61M$41.00M
净利润$57.14M−$33.36M$52.15M−$4.03M$124.45M
经营现金流$78.80M$137.85M$49.58M$97.05M$49.36M
自由现金流$70.04M$119.93M$46.06M$95.23M$48.91M
摊薄每股收益$3.31$-1.98$2.94$-0.22$6.13

Ligand Pharmaceuticals Incorporated LGND